Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5799426 | 0.84 | TACR2 (0.40) | ALDH1A1TDP1 | |
| SCHEMBL25365743 | 0.82 | ALDH1A1 (0.36) | MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL25366852 | 0.82 | SMN1; SMN2 (0.36) | MEN1KMT2AALDH1A1 | |
| SCHEMBL25367156 | 0.82 | MEN1 (0.37) | MEN1KMT2AALDH1A1 | |
| SCHEMBL25367612 | 0.80 | POLB (0.39) | MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL25365107 | 0.80 | KMT2A (0.42) | KMT2AALDH1A1 | |
| SCHEMBL25366451 | 0.80 | NPC1 (0.41) | MEN1KMT2AALDH1A1 | |
| SCHEMBL25365104 | 0.80 | KMT2A (0.42) | KMT2AALDH1A1 | |
| SCHEMBL25366273 | 0.78 | MAPK1 (0.41) | MEN1KMT2AALDH1A1 | |
| SCHEMBL25366278 | 0.78 | MAPK1 (0.41) | MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2024-01-18 | — | — | US | disclosed |
| CN-116568675-A | Cyclic isothiourea derivatives as CXCR4 modulators | 埃尔米乌治疗公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-4217353-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | Ermium Therapeutics (FR) | 2023-08-02 | — | — | EP | disclosed |
| US-20220144853-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | Université de Paris (FR) | 2022-05-12 | — | — | US | disclosed |
| US-20220144853-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | Université de Paris (FR) | 2022-05-12 | — | — | US | disclosed |
| WO-2022064075-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2022-03-31 | — | — | WO | disclosed |
| EP-3947394-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | Université de Paris (FR) | 2022-02-09 | — | — | EP | disclosed |
| CN-113939521-A | Imidazoline derivatives as CXCR4 modulators | 巴黎大学 | 2022-01-14 | — | — | CN | disclosed |
| WO-2020201096-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | Université de Paris (FR) | 2020-10-08 | — | — | WO | disclosed |
| US-7919630-B2 | Synthesis of imidazole 2-thiones via thiohydantoins | ALLERGAN, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919630-B2 | Synthesis of imidazole 2-thiones via thiohydantoins | ALLERGAN, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919630-B2 | Synthesis of imidazole 2-thiones via thiohydantoins | ALLERGAN, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20070203344-A1 | SYNTHESIS OF IMIDAZOLE 2-THIONES VIA THIOHYDANTOINS | ALLERGAN, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203344-A1 | SYNTHESIS OF IMIDAZOLE 2-THIONES VIA THIOHYDANTOINS | ALLERGAN, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203344-A1 | SYNTHESIS OF IMIDAZOLE 2-THIONES VIA THIOHYDANTOINS | ALLERGAN, INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007041048-A2 | SYNTHESIS OF IMIDAZOLE-2-THIONES VIA THIOHYDANTOINS | ALLERGAN, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041048-A2 | SYNTHESIS OF IMIDAZOLE-2-THIONES VIA THIOHYDANTOINS | ALLERGAN, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-7115748-B2 | Method of making imidazole-2-thiones | ALLERGAN, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| WO-2006062890-A1 | METHOD OF MAKING IMIDAZOLE-2-THIONES | ALLERGAN, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| US-20060122400-A1 | Method of making imidazole-2-thiones | ALLERGAN, INC. | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144853-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCL12, CXCR1 | MEN1 4426/4885KMT2A 4415/4885POLB 3550/4885 |
| US-20070203344-A1 | SYNTHESIS OF IMIDAZOLE 2-THIONES VIA THIOHYDANTOINS | TPMT, NISCH, IMPDH2 | MEN1 326/4885KMT2A 170/4885POLB 3768/4885 |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCR1, CXCL12 | MEN1 4670/4885KMT2A 4150/4885POLB 2906/4885 |
| US-20060122400-A1 | Method of making imidazole-2-thiones | TST, INMT, TPMT | MEN1 1081/4885KMT2A 652/4885POLB 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.